This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Americas

  1. The Safeprim study evaluated the operational aspects of the SD Biosensor STANDARD™ G6PD screening test performed in real-life settings of two municipalities in the Brazilian Amazon. In order to provide suitable training for health care professionals with different backgrounds at the primary level of care, job aids were created based on materials available within the G6PD Operational Research Community of Practice hosted by PATH. This way, the essential information on test procedure, treatment choice, and pharmacovigilance of hemolysis could be used in the field after a 4-hour training session.A wall poster (29.7x42 cm), folder (21x29.7 cm), and slide set were used during the trainings, while patient cards (8x20 cm malaria card) containing G6PD and malaria data were provided after screening: a green-colored card for normal G6PD status and red-colored card for G6PD deficient. Such cards could be referenced in future malaria episodes.
    Published: December 2021
    Type: Resource Page
  2. If we can't name the problem, we can't defeat it. Enter PATH's initiative to defeat diarrheal disease.
    Published: November 2021
    Type: Article
  3. Global convening of syringe manufacturers and multilateral organizations held to help bolster supply.
    Published: November 2021
    Type: Press Release
  4. This document, current as of November 11, 2021, provides data and information from PATH's COVID-19 modeling focused on the global autodisable (AD) syringe supply gap. This current forecast shows a gap of more than 1 billion safety syringes that could impact immunization efforts in 100 countries. The AD syringe gap analysis combines syringe supply capacity collected from manufacturers with estimated syringe demand from all countries known to use AD syringes globally, including demand for both COVID-19 and non-COVID-19 immunizations. The demand forecast for COVID-19 vaccination syringes is based on projected vaccine availability through the end of 2022 and includes secured bilateral deals, COVAX deals, donations, and other multilateral deals.
    Published: November 2021
    Type: Resource Page
  5. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included a feasibility and acceptability study with national stakeholders and healthcare providers in Ghana, Kenya, Malawi, Peru, Senegal, and Sri Lanka to assess their preferences for different hypothetical rotavirus vaccine options. These briefs provide an overview of the results in each of the study countries.
    Published: October 2021
    Type: Resource Page
  6. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included: targeted analyses on the ideal age group for iNGRVs and potential future combination vaccine options, impact and cost effectiveness analyses, a feasibility and acceptability study with national stakeholders and healthcare providers in six countries, and a demand forecast. This brief provides a comprehensive summary of the results.
    Published: October 2021
    Type: Resource Page
  7. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included an impact and cost-effectiveness analysis examining multiple rotavirus vaccine options and strategies. This fact sheet provides an overview of the results.
    Published: October 2021
    Type: Resource Page
  8. Research briefs in English and Portuguese on findings from a performance and operational use study of the SD Biosensor STANDARD™ G6PD Test in Brazil.The study shows that the SD Biosensor STANDARD G6PD Test performed well in comparison to the reference standard (spectrophotometry) which represents an important opportunity to improve Plasmodium vivax case management in malaria-endemic settings where reliable alternatives are needed to expand access to radical cure. The results of this study are relevant for the introduction of single-dose Kozenis in Brazil, which was approved in 2019.
    Published: October 2021
    Type: Resource Page
  9. The United States is among the largest funders of global health. As part of a global organization with a footprint in 70+ countries, the PATH team in Washington, D.C. leverages technical expertise to equip decision-makers with the information and evidence needed to make smart global health policy. In particular, we work with policymakers to ensure that funding for global health matches the scale of the challenges we face around the world, and that US global health polices and strategies are evidence-informed, ambitious, accountable, and—most importantly—promote equitable access to health. This brief gives a high-level overview of PATH as an organization, our impact, and our footprint in the United States.
    Published: August 2021
    Type: Resource Page
  10. The Partnership for Vivax Elimination (PAVE) will support endemic countries in achieving their Plasmodium vivax (P. vivax) malaria elimination goals.PAVE will advance the development of quality-assured, child-friendly treatments for relapse prevention, and generate and consolidate evidence to support malaria-endemic countries in developing and implementing new strategies to eliminate P. vivax malaria.
    Published: July 2021
    Type: Press Release
Load more